Stay updated on Fostamatinib Comb-Paclitaxel in Ovarian Cancer Clinical Trial

Sign up to get notified when there's something new on the Fostamatinib Comb-Paclitaxel in Ovarian Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Fostamatinib Comb-Paclitaxel in Ovarian Cancer Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the dose escalation study to determine the maximally tolerated dose of fostamatinib when administered with weekly paclitaxel in women with recurrent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer.
    Difference
    0.1%
    Check dated 2024-06-06T15:54:50.000Z thumbnail image
  4. Check
    5 days ago
    No Change Detected
  5. Check
    6 days ago
    No Change Detected
  6. Check
    18 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' on the webpage has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria.' This change represents an update in the eligibility criteria for potential participants in the clinical trial related to ovarian cancer research.
    Difference
    46%
    Check dated 2024-05-22T05:53:53.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Summary
    The value 'Go to the classic website Go to the classic website 5 2' on the webpage has been updated to 'type of intervention Site Map 6 0'. This change likely indicates a modification related to medical and healthcare-related publications and documentation.
    Difference
    0.9%
    Check dated 2024-05-01T17:35:21.000Z thumbnail image

Stay in the know with updates to Fostamatinib Comb-Paclitaxel in Ovarian Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Fostamatinib Comb-Paclitaxel in Ovarian Cancer Clinical Trial page.